A Phase 3 interventional study of Vasopressin administration and Sodium chloride administration in Septic Shock, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Assistance Publique Hopitaux De Marseille · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.
Among the 184 studies in Shock, Septic with a site in France, this one is the 52nd largest by planned enrollment of the 105 interventional ones that give a count, is one of 17 that started in 2026, is one of 25 in phase 3, reaches primary completion later than 36 of the 49 other live ones, and was the 166th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre National de la Recherche Scientifique, France · Sites in France
Ages 18–49 · Women only · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 19 · Phase 3 32 · Phase 4 9
First in 1997; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 120 across the 105 interventional studies, 100 across the 79 observational. Of the 108 that completed or were terminated, 6 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 184 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 6 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
13 of the studies in Shock, Septic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04748796Phase 3Centre Hospitalier Universitaire, AmiensComparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility | 2027-06 |
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT04067674Hospices Civils de LyonSeptic Shock-induced Immunosuppression | 2026-11-21 |
| NCT07354568Centre Hospitalier Universitaire, AmiensPrognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock | 2027-01-01 |
| NCT07199998Centre National de la Recherche Scientifique, FranceImpact of Internal Menstrual Protections on Immunity and Vaginal Microbiota | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 184 studies in Shock, Septic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Septic shock is a syndrome associated with severe infection and a mortality rate of approximately 45%. In line with current recommendations, norepinephrine is the first-line vasopressor used in patients with septic shock. In a previous study, norepinephrine doses above 1 µg/kg/min were associated with mortality rates over 90%. In the same study, doses above 0.3 µg/kg/min were associated with a mortality rate of 40%. An increased mortality compared to the general 40% mortality of septic shock appears to be associated with norepinephrine doses as low as 0.3 µg/kg/min.
Vasopressin stimulates V1 receptors, primarily located on vascular smooth muscle cells. When V1a receptors are stimulated, they induce vasoconstriction by activating protein kinase C via a Gq protein and various second messengers.
Its use is validated in refractory shock states by international guidelines as a second-line vasopressor. This indication was further reinforced in the 2021 update of the septic shock management recommendations.
The VASST study, a randomized controlled trial, assessed the effects of vasopressin versus norepinephrine in septic shock. It found no overall difference in mortality between the two groups. However, in less severe cases where norepinephrine doses were below 14 µg/min before randomization, vasopressin was associated with significantly lower mortality, suggesting potential benefits from early introduction of a second vasopressor.
The VANISH trial failed to confirm this hypothesis, possibly due to broad inclusion criteria and unclear protocol regarding the combined use of both agents. Our hypothesis is that (1) vasopressin is beneficial when used synergistically with norepinephrine; (2) due to its negative effect on cardiac output (as shown in previous studies), vasopressin should only be administered to patients in the hyperdynamic phase of septic shock.
The hypothesis is that the systematic addition of vasopressin to norepinephrine therapy in a hyperdynamic septic shock subpopulation would improve patient outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vasopressin administration
Drug: Sodium chloride administration
Low dose of vasopressin (0.02ui /min), maximum 5 days
NaCl 0.9 %, maximum 5 days
SOFA score comparison between the two groups
Sepsis-related Organ Failure Assessment, 0 to 24 points (higher scores indicate more severe organ dysfunction)
Time frame: 48 hours after administration of experimental drug (H48)
SOFA score comparison between the two groups
Sepsis-related Organ Failure Assessment, 0 to 24 points (higher scores indicate more severe organ dysfunction)
Time frame: 120 hours after administration of experimental drug (H120)
Mortality comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Lactatemia decrease comparison between the two groups
Time frame: Between administration of experimental drug (H0), 24 hours after (H24), and 48 hours after (H48)
Noradrenaline use comparison between the two groups
Maximum dose
Time frame: 5 days after administration of experimental drug (D5)
Renal function comparison between the two groups
Number of days alive without renal replacement therapy
Time frame: 28 days after administration of experimental drug (D28)
Respiratory function comparison between the two groups
Number of days alive without mechanical ventilation
Time frame: 28 days after administration of experimental drug (D28)
Occurrence of myocardial ischemia comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Occurrence of cardiogenic shock comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Occurrence of mesenteric ischemia comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Occurrence of digital ischemia comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Occurrence of atrial fibrillation comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Occurrence of a thromboembolic event comparison between the two groups
Time frame: 28 days after administration of experimental drug (D28)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 23 months after the start.
Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 23 months is below that.
Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →